OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
January 3, 2025
OS Therapies, a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, has partnered with B2i Digital to enhance investor outreach. B2i Digital will